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Brief communication
Variable skeletal phenotypes 
associated with biallelic 
variants in PRKG2
The 100 000 Genomes Project (100KGP) 
is a UK- wide initiative that has a goal of 
using whole genome sequencing (WGS) 
to identify genetic causes of rare inher-
ited diseases and embed the use of this 
technology within the NHS.1 Using data 
from this resource alongside interna-
tional gene- matching efforts, four indi-
viduals from two independent families 
were identified harbouring homozy-
gous frameshift or stop- gain variants 
in PRKG2, a recently described skeletal 
dysplasia gene.2 Detailed clinical and 
radiological assessments helped extend 
the phenotypic range associated with 
this autosomal recessive condition while 
functional studies indicated that both 
variants had a similar impact on FGF- 
induced MAPK signalling.
PRKG2 encodes the cyclic guanosine 
monophosphate dependent protein kinase 
II (cGKII), which acts downstream of the 
natriuretic peptide receptor- B/C- natri-
uretic peptide (NPR- B/CNP). NPR- B is 
encoded by NPR2, biallelic variants in 
which are responsible for acromesomelic 
dysplasia, Maroteaux type (AMDM; MIM 
602875). Rodent models further impli-
cate PRKG2 in skeletal development3 4 
and cGKII deficiency was shown to be the 
cause of the dwarfism phenotype observed 
in Angus cattle.5 Building on support 
from pathway analysis and model organ-
isms, a recent study showed that biallelic 
PRKG2 variants can result in acrome-
somelic dysplasia, PRKG2- type (AMDP) in 
humans,2 adding PRKG2 to a list of >400 
genes associated with genetic skeletal disor-
ders.6 As only two affected individuals 
were reported, it is important that the full 
clinical range of this condition is described.
In this study, we searched for rare bial-
lelic PRKG2 variants using data from 
the 100KGP via the LabKey applica-
tion available within Genomic England’s 
research environment. Researchers can 
apply for access online ( www. genom-
icsengland. co. uk/ join- a- gecip- domain). 
Initial filtering employed a 1% population 
allele frequency threshold based on data 
from the 1000 Genomes Project as well as 
in- house frequency information. An addi-
tional family was identified via a network 
of collaborators and variants were classi-
fied using ACMG criteria (online supple-
mental table 1).
In family 1, WGS and subsequent 
Sanger sequencing uncovered a homo-
zygous pathogenic PRKG2 variant, 
NM_006259.3:c.2282dup (p.Asp-
761Glufs*34; online supplemental figure 1) 
in three brothers referred with spondylome-
taphyseal dysplasia (figure 1A). Interestingly, 
the middle- affected brother (F1- IV- 6) also 
has type I osteogenesis imperfecta (OI). An 
early clinical exome sequencing study found 
that for 4.6% of cases with a molecular 
diagnosis, more than one gene was contrib-
uting to a blended phenotype.7 Complex 
cases such as these are expected to be more 
common in highly consanguineous fami-
lies where large regions of homozygosity 
(ROHs) make up a significant proportion 
of the genome; however, for F1- IV- 6 the 
secondary diagnosis of OI was due to a 
COL1A1 frameshift, which had arisen de 
novo. OI was suspected in this child because 
of multiple fractures in childhood (arm 
as an infant, wrist aged 8 and thoracic T6 
wedge fracture) combined with blue sclerae. 
It is certainly possible that the coexistent OI 
may have had an impact on the severity of 
the phenotype in this individual, not least 
because his height was more significantly 
reduced than for his two brothers and OI 
(type 1) is a known cause of reduced stature 
in its own right.
In family 2, exome sequencing for a girl 
with acromesomelic dysplasia revealed a 
homozygous pathogenic PRKG2 variant 
c.1705C>T; p.(Arg569*) (online supple-
mental figure 2), observed previously in a 
patient with similar clinical and radiolog-
ical features.2 Comparison of the available 
genomic data for F2- V- 3 and the previ-
ously published case was not able to detect 
a shared haplotype across the PRKG2 
locus. However, exome sequencing has 
limited resolution to detect small regions 
of identity by descent and so a founder 
mutation cannot be ruled out. Given 
the differing ethnicities and the fact that 
c.1705C>T lies at a CpG dinucleotide, 
the recurrence of c.1705C>T being due 
to separate mutational events seems a 
more likely scenario.
Both variants described here are 
extremely rare; p.(Asp761Glufs*34) is 
absent from gnomAD (https:// gnomad. 
broadinstitute. org), while p.(Arg569*) is 
present as a singleton allele. In both fami-
lies, the disease- causing variants lay within 
large ROHs (online supplemental table 2). 
Pathogenic variants are overrepresented in 
the largest ROHs and it has been proposed 
that lying in one of the top 10 such regions 
can be used as evidence supporting patho-
genicity.8 While the p.(Arg569*) variant 
has already been demonstrated to affect 
the downstream MAPK pathway,2 the 
p.(Asp761Glufs*34) in family 1 is likely 
to be disruptive given the switch of the 
final Asp- Phe residues for 33 alternative 
amino acids at the C terminus. In silico 
modelling highlights the structural impor-
tance of this region, in particular the final 
Phe762 residue (figure 1B, supplementary 
methods; interactive version at https:// 
michelanglo. sgc. ox. ac. uk/ r/ prkg2).
To functionally confirm the patho-
genicity of the newly identified 
p.(Asp761Glufs*34) variant, we first 
analysed cGKII expression by western 
blot analysis. Plasmid construction 
for p.(Asp761Glufs*34) involved a 
sequential PCR strategy (supplemental 
methods), with the previously charac-
terised p.(Arg569*) variant employed 
as a positive control. For both variants, 
cGKII was detected at the predicted 
size (figure 1C), although at dramati-
cally reduced levels (≥80%) compared 
with the wild type (figure 1D). Next, 
we evaluated whether the p.Asp-
761Glufs*34 mutant was able to 
inhibit FGF2- induced MAPK pathway 
by analysing its ability to induce phos-
phorylation of Raf- 1 at Ser- 43 and 
ERK1/2, as described previously.2 
Wild- type cGKII downregulated MAPK 
signalling by reducing ERK1/2 acti-
vation through the upstream phos-
phorylation of Raf- 1 at Ser- 43 in a 
cGMP- dependent manner. However, 
the p.Asp761Glufs*34 mutant failed 
to phosphorylate Raf- 1 at Ser- 43 and 
thus, reduced FGF2- induced ERK1/2 
phosphorylation (figure 1E–F), similar 
to results for the p.Arg569* variant.2
Detailed phenotypic information is 
provided for both families and compared 
with the two published cases (online 
supplemental table 2, figure 3). Radio-
logical findings for F2- V- 3 were very 
similar to those observed for ‘Proband 
1’ described previously,2 which is 
unsurprising given that both individ-
uals harbour the same homozygous 
p.(Arg569*). In contrast, for PRKG2 
family 1 there was a consistent radio-
logical phenotype distinct from previ-
ously reported AMDP and AMDM. The 
three brothers reported here (F1- IV- 3, 
IV- 6 and IV- 7) had no evidence of acro-
mesomelic shortening, except for mild 
shortening of toes observed for indi-
vidual F1- IV- 7. The main findings were 
platyspondyly with anterior vertebral 
body projections, long slender femoral 
necks and some metaphyseal irregularity 
(most evident in the radius and ulna) 
and striations (figure 2). The metaphyses 
of the distal phalanges were some-
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pronounced, generalised or associated 
with shortening, as seen in AMDM.9 
In summary, family 1 exhibited a skel-
etal phenotype characterised by spon-
dylometaphyseal dysplasia, rather than 
acromesomelic dysplasia as expected in 
AMDP and AMDM.
Interestingly, the PRKG2 locus has been 
identified in several genome- wide asso-
ciation studies on height ( www. ebi. ac. 
uk/ gwas/ genes/ PRKG2). Therefore, the 
description of this now confirmed Mende-
lian condition constitutes an additional 
example of rare variants in a gene causing 
a severe condition, where common vari-
ants in the same gene are associated with 
a related trait.10 In summary, analysis 
of 100KGP data combined with gene- 
matching efforts identified four affected 
individuals with biallelic loss of func-
tion variants in PRKG2, extending the 
Figure 1 Pedigrees, structural modelling and the effects of the PRKG2 variants on cGKII protein levels/MAPK pathway regulation. (A) Simplified pedigrees 
and segregation of variants in PRKG2 and COL1A1 in two families with rare skeletal dysplasias. More detailed pedigrees are shown in online supplemental 
figure 4. AMD, acromesomelic dysplasia (mild); ND, not determined; OI, osteogenesis imperfecta; SMD, spondylometaphyseal dysplasia; WT, wild- type; *, 
WGS performed as part of 100KGP; +, exome sequencing. The COL1A1 variant was initially detected by targeted sequencing in 2011 but confirmed to have 
arisen de novo by WGS. (B) Structure of cGKII (wild type: turquoise) with overlay of the mutant, p.Asp761Glufs*34 (salmon) extension and inset of Phe762 
residue. The protein kinase domain is regulated by two cyclic nucleotides binding (CNB) domains. The predicted C- terminal extension would fall between 
CNB- A domain and the protein kinase domain and is likely to interfere with the activation of the latter by the former, were it to be stable, a conclusion not 
supported by in silico predictions. In fact, the extension results in a deleterious amino acid change of a core residue, Phe762, to a leucine (inset). Also visible 
is the hydrogen bond between the terminal carboxylate and Thr519, whereas the amide bond between Leu762 and Leu763 is forced away in order to best 
accommodate the subsequent residues. (C) Immunoblotting results for cGKII (upper panel) and GAPDH as an endogenous control (lower panel) of cell 
lysates extracted from transiently transfected HEK293T cells. Both human cGKII mutants as well as wild- type (WT) proteins were detected at their predicted 
size: R569*: 65.1 kDa and D761Efs*34: 91.1 kDa (calculated by using the ExPaSy online tool, https://web.expasy.org). (D) Densitometry quantification of 
cGKII showing that there is an 80% reduction in expression of the two mutants compared with WT. (E) Western blots of phosphorylated Raf- 1 and ERK1/2 
proteins of the MAPK pathway showed that neither of the mutants were able to phosphorylate c- Raf at Ser43 and therefore downregulate ERK activation 
compared with WT in response to FGF2 induction in transiently transfected HEKT293 cells. (F) Densitometry quantification of pMAPK 44/42 protein revealed 
that neither R569* nor D761Efs*34 mutants were able to downregulate FGF2- induced ERK1/2 activation compared with WT, in transiently transfected 
HEK293 cells in the presence of 8- pCPT- cGMP. Three biological experiments were performed, and significance values are represented as *p<0.05, 
**p<0.01, ***p<0.001 and ****p>0.0001. EV, empty vector; T−, untransfected cells.
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phenotypic range of this condition to 
include spondylometaphyseal dysplasia. 
The patients described here were the only 
individuals harbouring severe biallelic 
PRKG2 variants across all rare disease 
areas within the 100KGP. These data 
include 295 patients recruited due to 
an unexplained skeletal dysplasia and 
therefore our results are consistent with 
this condition being extremely rare in 
humans.
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and hypoplasia of the L2 vertebral body. (E) Left hand radiograph at age 11 in same child shows no 
brachydactyly; there is mild metaphyseal chondrodysplasia evident in the distal radius and particularly 
the ulna, with some metaphyseal striations (black arrow); subtle coning of the distal phalangeal 
metaphyses is evident (white arrows), without associated shortening. Pelvic (F) and lateral spine (G) 
radiographs in middle affected sibling (F1- IV- 6) in family 1 showing similar features of long slender 
femoral necks and platyspondyly with anterior vertebral body projections. Osteopaenia is also evident; 
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(J) Pelvic radiograph from F2- V- 3 demonstrates mildly elongated femoral necks. (K) Lateral spine 
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Table S2: Clinical details and variant information for four individuals from two independent families with biallelic variants in PRKG2 .  Results are compared to two cases reported by Díaz-González et al 2020.
Sequencing methods in Family 2 are as described by Pagnamenta et al  2021. NA, not available; ROH, region of homozygosity.  Variant annotation is based on NM_006259.3.  SDs for adults heights were calculated
using https://tall.life/height-percentile-calculator-age-country. For Family 1 we used the mean adult height obtained from the Royal College of Paediatrics and Child Health's standard growth chart.
Family/individual ID Family 2 Proband 1 Proband 2
Consanguinity (parental 
relationship)
Yes (double 2nd cousins) Yes (3rd cousins) Yes (3rd cousins)
Ethnicity Iranian Moroccan Indian
Parents' stature
Father 155 cm (-2.10 SD);                     
Mother 171 cm (1.90 SD)
Father 165 cm (-1.75 SD);            
Mother 164 cm (-0.01 SD)
Father 158 cm (-2.59 SD);               
Mother 147 cm ( -2.50 SD)
Individual IV-3 IV-6 IV-7 V-3 II-2 II-2
Gender (M/F) M M M F F F
Age at first referral 13 years 8 months 2 years 3 years NA 4 years
Referral reason Diagnosis due to sibling
Poor weight gain, unusual limb 
proportions, hypotonia, large 
head
Short stature Short stature/dysmorphism 
Short stature/suspected skeletal 
dysplasia
Short stature/suspected skeletal 
dysplasia











chr4: 30,724,365-89,247,731             (58.5Mb) NA NA
Hypotonia NA Yes N/A No - -
Birth weight 2700 g N/A N/A 3350 g NA NA
Birth length N/A N/A N/A 50 cm NA (−1.93 SDS at 3 weeks) NA
Birth OFC N/A N/A N/A 34 cm NA (−0.42 SDS at 3 weeks) NA
Developmental 
milestones
Normal Normal Normal Normal Normal Normal
Growth / feeding No concerns until 4y Poor feeder NA Normal NA NA
Age at last assessment 
(years)
26 22 15 10 12 11
Height (Percentile/SD) 158.5 cm (-2.5 SD) 140.8 cm (-4.9 SD) 143.8 cm (-3.11 SD) 121 cm (-2.5 SD) -4.01  SD −5.06 SD
Sitting height (cm) 85 76 77 70 NA NA
Leg length NA -2 to -3 SD NA 53 NA NA
Skeletal proportions
Mild rhizomelia of upper and 
lower limbs
Moderate rhizomelia of upper 
and lower limbs
Mild rhizomelia of upper and 
lower limbs
Rhizomelic  shortening of the upper and 
lower extremities.
Mild mesomelic shortening of the 
limbs (lower limbs, radius and 
ulna); sitting height to height ragio 
was 0.579 (1.21 SDs)
No (upper to lower segment ratio 
1.41 aged 11y)
OFC (centile) 50-75th 50-75th 50-75th 56cm - -
Kyphosis Yes, mild, thoracic region Yes, mild, mid-thoracic - No - -
Digital anomalies
Normal except for broad thumbs 
and short 4-5th metacarpels
Normal except for broad thumbs - Short, broad fingers Short, stubby fingers Short stubby fingers
Acromelia No No No No - -
Feet Flat feet 
NA
Mild shortening of toes 
(Figure S3A bottom)
Short broad toes - Sandal gap
Facial appearance Normal Triangular face,  when younger Normal
Broad nasal bridge, thick eyebrows, 
synophrys, prominent chin
Normal
Triangular face, broad nasal bridge, 
pointed chin, synophrys, 
hypertelorism, low set ears. 
Cranial findings NA Multiple Wormian bones NA Normal Normal Normal
Palate Normal Normal Normal Normal - -
Platyspondyly Yes Yes Yes (mild) Yes
Yes (mild flattening of the thoracic 
vertebral bodies)
Moderate platyspondyly with 
anterior beaking of vertebral 
borders of dorsolumbar spine
Metaphyseal changes Yes (widespread) Yes Yes (broadened and irregular) Yes -
Long bones showed relatively large 
epiphyses and widening, with some 
irregularity of the metaphyses. 





Slender bones with thin cortices, 
mild bowing of femur, small 
irregular femoral heads
-
Short metacarp and metatarsal + disostosis 
peripheral
Mild thoracic scoliosis, lumbar 
hyperlordosis, short pedicles of the 
lumbar spine, very mild flaring of 
the metaphyses and mild genu 
valgum. Growth plate of knee was 
prematurely fused, radius and ulna 
mildly bowed; short broad 
phalanges and metacarpals 
(especially 3-5th), all prematurely 
fused
Prominent deltoid tuberosities of 
the humeri, short and broad 
phalanges, ilia short with flaring of 
the iliac wings, vertebral alterations 
less prominent and restricted to the 
thoracic region with mild shortening 
of the pedicles of her lumbar spine.  
Pelvic radiograph showed minor 
irregularity of the acetabula
Bone age Delayed NA NA No delay (9 years at calendar age of 9) Advanced (+2.6 SD) Within normal limits
Bone density Normal NA Normal NA NA NA
Suggested diagnoses 




(SMD)-type not classified and 
Osteogenesis Imperfecta type 1
Spondylometaphyseal 
dysplasia (SMD)-type not 
classified
Pseudoachondroplasia
Similar to AMDM but with milder 
radiological phenotype, no cone-




Multiple fractures (arm as infant, 
wrist aged 8y, wedge T6 
vertebra), blue sclerae
-
Constipation, umbilical hernia in the past 
(now normal), hypertrichosis
-
Hirsutism, prominent costochondral 
cartilages, sternal prominence,
widening of wrists, genu varum 
Cardiovascular - - - Normal




Good response seen in 6m GH 
trial aged 14 and a half years. 
During this time his annual 
growth velocity increased 
significantly (3.4 to 7.6 cm/yr).
Pamidronate
Successful trial of Growth 
Hormone (treatment 
ongoing) and showing good 
response (currently 4.6 
cm/year).
Somatropin injections (3 months)
Femoral and humeral limb 
lengthening
-
Sequencing method Sanger sequencing
Exome sequencing as described previously 
(PMID: 33559681)
Trio exome sequencing using Sure 
Select Human All exon V6 targeted 
capture (Agilent Technologies), 
paired-end 150 bp sequencing on 
NovaSeq6000
Nextera Expanded exome kit 
(Illumina) and paired-end 100 bp 
sequencing on a HiSeq2000
Genetic testing prior to 
WGS/exome
-
COL1A1/COL1A2  testing detected 
COL1A1: 
NM_000088.4:c.1770del; 
p.(Glu591Serfs*175) de novo. 
Normal karyotype.
Array CGH (60K), SHOX 
sequencing and MLPA all 
normal 
-
Custom-designed NGS skeletal 
dysplasia panel (327 genes)
-
Díaz-González et al 2020
Yes (double 1st cousins)
Pakistani
Family 1
150 bp paired end sequencing on HiSeqX as part of 100K 
Genomes Project, Truseq PCR-Free High Throughput library.  
Sequenced with parents as quod.
Father 177 cm (0 SD);                                                                           
Mother 160 cm (-0.60 SD)
 c.2282dupA; p.(Asp761Glufs*34) 
Absent
Families reported here
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Variable skeletal phenotypes associated with biallelic variants in PRKG2 
 
 
Figure S1: Sanger sequencing electropherogram validating the PRKG2 variant in Family 1 NM_006259.3: 
c.2282dupA; p.(Asp761Glufs*34) which lies close to the wild-type C-terminus.  Heterozygosity in parental 
samples was already confirmed by WGS. 
 
Figure S2: Sanger sequencing electropherogram showing the PRKG2 variant in Family 2 NM_006259.3: 
c.1705C>T; p.(Arg569*) to be homozygous in the proband and heterozygous in a parental sample. 
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Figure S3: Photos showing clinical features of note.  A) Photo showing of the toes in Family 1 which were 
unremarkable for F1-IV-3 (top) and F1-IV-6 (middle), but with mild shortening seen for F1-IV-7 (bottom). B) 
Photo showing short/broad fingers in individual F2-V-3 (aged 10 years). C) Photo showing subtle dysmorphic 
features in F2-V-3, with thick eyebrows, synophrys and a broad nasal bridge. 
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Figure S4: Full pedigrees and segregation of variants in PRKG2 and COL1A1 for 2 families with rare skeletal 
dysplasias. Pedigrees are shown in same order as the simplified versions in Figure 1A.  SMD, 
Spondylometaphyseal dysplasia; OI, Osteogenesis imperfecta; AD, Acromesomelic dysplasia (mild); WT, wild-
type; ND = not determined; *, genome sequencing performed as part of 100KGP, +, exome sequencing. 
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The empty Myc-DDK-tagged expression pCMV6-Entry plasmid as well as the human PRKG2 (NM_006259.2; 
pCMV6-PRKG2-WT) wild type plasmids were obtained from Origene Technologies (Rockville, MD). The 
PRKG2 p.R569* mutant was generated as previously reported.5  The p.D761Efs*34 mutant was generated by two 
sequential PCRs in order to add the extra nucleotide sequence to the C-terminus of the wild type sequence. The 
PCR-1 primers were 5' CCGCCGCGATCGCCATGGGAAATGGTTCAGTGAAACCTAAACATTCTA-
AGCACCCAGATGGACAC3' (forward) and 5' CTTCTGTAGAGTACAGGCAGTAATCAACTTTT-
CTTCTGTCAGAAGTTCTTTATCCCAGCCTGATAGC 3´ (reverse). The product of PCR-1 was then submitted 
to a second PCR (PCR-2) to add the remaining nucleotides to complete the mutated sequence. The same forward 
primer was used in PCR-2 whilst 5' GTACGCGTTAATACTCTGAAAAGAAAATAATGTGTTGGATTATTG-
ATCCTTGAGGTCCTCTTCTGTAGAGTACA 3´ was employed as the reverse primer.  The PCR product was 
then cloned into a pCR2.1 vector by TA cloning method following manufacturer´s instructions (Life 
Technologies, Carlsbad, CA). Next, the cloned fragment was subcloned into pCMV6 vector using the pCMV6-
PRKG2-WT construct digested with SgfI and MluI enzymes (Thermo Fisher Scientific) resulting in the pCMV6-
PRKG2-D761Efs*34 mutant plasmid. The construct was verified by Sanger sequencing. 
MAPK pathway analysis 
Cell culture, transient transfections, Western blots and densitometry quantification were performed as previously 
described.5 
Table S1:  Variant interpretation using ACMG guidelines.6 





ACMG evidence codes PVS1 (applied with caution as near 3’ end but 
N.B. 33 additional residues and WB data in 
Fig 1C,D supports use), PS3 (MAPK 
signalling affected, Fig 1E,F), PM2 (absent in 
gnomAD), PP1 (cosegregation, Fig 1A), PP3 
(structural modelling, Fig 1B) 
PVS1, PS3 (Diaz-Gonzalez 
et al5 and now replicated), 
PM2 (singleton allele in 
gnomAD 2.1.1), PP3 (in 
silico e.g. CADD=37) 
ACMG classification Pathogenic  Pathogenic 
 
Table S2: Clinical details and variant information for four individuals from two independent families with 
biallelic variants in PRKG2.  Results are compared to two cases reported by Díaz-González et al 2020.5 
Sequencing methods in Family 2 are as described by Pagnamenta et al 2021.7 NA, not available; ROH, region of 
homozygosity.   Variant annotation is based on NM_006259.3. SDs for adults heights were calculated using 
https://tall.life/height-percentile-calculator-age-country. For Family 1 we used the mean adult height obtained 
from the Royal College of Paediatrics and Child Health's standard growth chart 
 
N.B. This table is provided as a separate xlsx file. 
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